Printer Friendly

BIOMIRA ANNOUNCES RESULTS TO JUNE 30, 1992

 BIOMIRA ANNOUNCES RESULTS TO JUNE 30, 1992
 EDMONTON, Alberta, July 29 /PRNewswire/ -- Biomira Inc.


(NASDAQ: BIOMF; Toronto, Montreal, Calgary: BRA) announced today its financial results for the six months ended June 30, 1992.
 Revenues for the six months ended June 30, 1992 were $11.4 million compared to the corresponding period in 1991 of $10.1 million. The increase in revenue of 13 percent principally reflects increased interest revenue of $1.6 million due to significantly higher cash balances in the corporation. The consolidated net loss for the period of $6.2 million (June 1991 loss - $3.8 million) represents a loss per share of $0.34 (June 1991 - $0.31) on a weighted average number of common shares outstanding of 18.0 million (June 1991 - 12.4 million).
 Biomira's 46-percent-owned affiliated company, ADI Diagnostics Inc., is accounted for on the equity basis and has resulted in a loss for the six months ended June 1992 of $1.3 million (June 1991 loss - $1.1 million).
 The company continues to invest significant cash resources in research and development and for expenses related to clinical trials, all of which are expensed as incurred. These expenditures will continue to increase over the next few years as the company proceeds through the rigorous regulatory approval process prior to commercialization.
 Cash balances in the corporation at June 30, 1992 are $43.7 million compared to $7.2 million at June 30, 1991 as a result of the issue of 4.36 million common shares in December 1991.
 Biomira is a public biotechnology firm which has four in vitro test kits on the market under the TRUQUANT (R) label for diagnosing gastrointestinal, ovarian, and breast cancers, including one for measuring the probability of human anti-mouse antibody (HAMA) reaction. A number of other products, including THERATOPE (R) therapeutic injections, and Tru-Scint (R) diagnostic radioimmunoconjugates, are at various phases in the clinical trial process. Biomira holds a 75 percent interest in H.C.S. Health Care Systems Inc. of Vancouver, and a 46 percent interest in ADI Diagnostics Inc. of Toronto.
 -0- 7/29/92
 /CONTACT: Alex McPherson, M.D., Ph.D., president and CEO, or Jim Devaney, C.A., VP-finance and CFO, or Jane Jack, (investors), 403-490-2812/
 (BIOMF) CO: Biomira Inc. ST: Alberta IN: SU: ERN


AL -- LA029 -- 4796 07/29/92 17:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 29, 1992
Words:389
Previous Article:USX ANNOUNCES APPOINTMENT, RETIREMENT
Next Article:CITY LOOKS INTERNATIONAL ANNOUNCES OPENING OF SALONS IN CHICAGO AREA
Topics:


Related Articles
STERLING WINTHROP AND BIOMIRA SIGN AGREEMENTS FOR THE DEVELOPMENT OF ANTIBODY-BASED CANCER PRODUCTS
BIOMIRA AND STERLING WINTHROP SIGN AGREEMENTS FOR THE DEVELOPMENT OF ANTIBODY-BASED CANCER PRODUCTS
BIOMIRA ANNOUNCES EXCLUSIVE WORLD RIGHTS TO PEPTIDE ANTIGEN COULD LEAD TO 'DESIGNER DRUGS' AGAINST COMMON CANCERS
BIOMIRA INC. ANNOUNCES THAT TWO OF ITS FOUNDERS SELL SMALL PORTION OF THEIR SHARES
BIOMIRA ANNOUNCES 1992 FIRST QUARTER FINANCIAL RESULTS
BIOMIRA INC. ANNOUNCES 3RD QUARTER FINANCIAL RESULTS
BIOMIRA INC. ANNOUNCES SECOND QUARTER RESULTS
BIOMIRA INC. ANNOUNCES THIRD QUARTER RESULTS
BIOMIRA ESTABLISHES SECOND LICENSE AGREEMENT WITH BEHRINGWERKE A.G.
BIOMIRA INC. PURCHASES REMAINING SHARES OF ADI FROM CAMBRIDGE BIOTECH CORPORATION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters